APHIS HomeAbout APHISNewsroomCareer OpportunitiesHelpContact Us
Decrease Font Size Increase Font Size
Search

USDA in Facebook APHIS in Twitter APHIS in Youtube APHIS Stakeholder Registry APHIS in Pictures APHIS in Blog APHIS RSS News Feeds

Browse by Subject
Animal Health
Animal Welfare
Biotechnology
Emergency Preparedness and Response
Import and Export
International Services
Permits
Plant Health
Regulations and Assessments
APHIS User Fees
Wildlife Control and Management
Animal Health

Risk Analysis for Veterinary Biologics

Divider

The Center for Veterinary Biologics uses risk analysis procedures to evaluate: (i) license applications for new live conventionally derived and biotechnology-derived veterinary biologics, and (ii) proposals to import veterinary biologics into the United States. The following Summary Information Formats (SIFs) and Risk Assessment (RA) Outline identify the relevant information that should be evaluated in Veterinary Biologics risk analyses. See Veterinary Services Memorandum 800.205 (PDF 19KB) for additional guidance.

Summary Information Format for Conventionally Derived Live Veterinary Biologics (PDF 14KB)
This SIF is designed to identify the appropriate information that should be provided to properly characterize the vaccine microorganisms for conventionally derived live vaccines. The characterization of the vaccine microorganism is based on its microbiological and biological properties, and those of the parental microorganism from which the vaccine strain was derived.

SIF Category I Veterinary Biologics (PDF 16KB)

  Subcategories
I-A-1 non-replicating recombinant antigens--therapeutic/prophylactic use
I-A-2 non-replicating recombinant antigens--diagnostics
I-B-1 monoclonal antibodies--therapeutic/prophylactic use
I-B-2 monoclonal antibodies--diagnostics
I-C-1 synthetic peptides --therapeutic/prophylactic use
I-C-2 synthetic peptides --diagnostics
I-D-1 nucleic acid-mediated--therapeutic/prophylactic use
I-D-2 nucleic acid-mediated--diagnostics

It is not anticipated that inactivated microorganisms will pose a threat to the environment. Accordingly, the risk analysis process is used to ensure that the biotechnology-derived microorganism is properly characterized and inactivated, rather than to evaluate proposed environmental releases of inactivated products.           Example of Category I SIF


SIF Category II Veterinary Biologics (PDF 19KB)

Category II biologics include biotechnology-derived live vaccines containing gene deletions and\or heterologous marker genes.          Example of Category II SIF

                                                               Page     1     2

 

 

Last Modified: January 19, 2011


VS Stakeholders Registry
VS Logo